Catella-Lawson F - Search Results

1

Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids.

Catella-Lawson F, McAdam B, Morrison BW, Kapoor S, Kujubu D, Antes L, Lasseter KC, Quan H, Gertz BJ, FitzGerald GA. Catella-Lawson F, et al. J Pharmacol Exp Ther. 1999 May;289(2):735-41. J Pharmacol Exp Ther. 1999. PMID: 10215647 Clinical Trial.

2

Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2.

McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. McAdam BF, et al. Among authors: catella lawson f. Proc Natl Acad Sci U S A. 1999 Jan 5;96(1):272-7. doi: 10.1073/pnas.96.1.272. Proc Natl Acad Sci U S A. 1999. PMID: 9874808 Free PMC article.

3

Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.

Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, Vyas SN, FitzGerald GA. Catella-Lawson F, et al. N Engl J Med. 2001 Dec 20;345(25):1809-17. doi: 10.1056/NEJMoa003199. N Engl J Med. 2001. PMID: 11752357 Free article. Clinical Trial.

4

Long-term aspirin in the prevention of cardiovascular disorders. Recent developments and variations on a theme.

Catella-Lawson F, FitzGerald GA. Catella-Lawson F, et al. Drug Saf. 1995 Aug;13(2):69-75. doi: 10.2165/00002018-199513020-00001. Drug Saf. 1995. PMID: 7576265 Review. No abstract available.

5

Oxidative stress and platelet activation in diabetes mellitus.

Catella-Lawson F, FitzGerald GA. Catella-Lawson F, et al. Diabetes Res Clin Pract. 1996 Feb;30 Suppl:13-8. doi: 10.1016/s0168-8227(96)80033-7. Diabetes Res Clin Pract. 1996. PMID: 8964187 Free article. Review.

6

Oral delivery of anticoagulant doses of heparin. A randomized, double-blind, controlled study in humans.

Baughman RA, Kapoor SC, Agarwal RK, Kisicki J, Catella-Lawson F, FitzGerald GA. Baughman RA, et al. Circulation. 1998 Oct 20;98(16):1610-5. doi: 10.1161/01.cir.98.16.1610. Circulation. 1998. PMID: 9778325 Clinical Trial.

7

Oral glycoprotein IIb/IIIa antagonism in patients with coronary artery disease.

Catella-Lawson F, Kapoor S, Moretti D, De Marco S, Vigilante GJ, Cucchiara AJ, Ramsey KE, Combe S, Rocca B, Theroux P, FitzGerald GA; AFIRME Investigators. Antagonism of the Fibrinogen Receptor after Myocardial Events. Catella-Lawson F, et al. Am J Cardiol. 2001 Aug 1;88(3):236-42. doi: 10.1016/s0002-9149(01)01632-0. Am J Cardiol. 2001. PMID: 11472700 Clinical Trial.

8

Effect of the Pl(A2) alloantigen on the function of beta(3)-integrins in platelets.

Bennett JS, Catella-Lawson F, Rut AR, Vilaire G, Qi W, Kapoor SC, Murphy S, FitzGerald GA. Bennett JS, et al. Among authors: catella lawson f. Blood. 2001 May 15;97(10):3093-9. doi: 10.1182/blood.v97.10.3093. Blood. 2001. PMID: 11342435 Free article.

9

Cyclooxygenase inhibition and thrombogenicity.

Catella-Lawson F, Crofford LJ. Catella-Lawson F, et al. Am J Med. 2001 Feb 19;110 Suppl 3A:28S-32S. doi: 10.1016/s0002-9343(00)00683-5. Am J Med. 2001. PMID: 11173047 Review.

10

Confusion in reperfusion. Problems in the clinical development of antithrombotic drugs.

Catella-Lawson F, FitzGerald GA. Catella-Lawson F, et al. Circulation. 1997 Feb 18;95(4):793-5. doi: 10.1161/01.cir.95.4.793. Circulation. 1997. PMID: 9054731 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

15 results

Search Page

Filters